Chemistry
Explore this Section
- / School of Chemical and Physical Sciences /
- Chemistry and Medicinal Chemistry /
- People /
- Tess Phillips
I graduated from the University of Cambridge with a Masters degree in Natural Sciences, specialising in Chemistry. I stayed on in Cambridge to complete a PhD under the supervision of Prof. Andrew Holmes, investigating how palladium-catalysed reactions can be conducted using environmentally benign carbon dioxide as an alternative to traditional organic solvents.
After completing my PhD, I worked as a medicinal chemist at the Cambridge based biotech company Astex Technology, where I was part of drug discovery teams on a number of oncology projects.
I then moved back into academia, joining The University of Manchester to take up a position as a postdoctoral research associate in Prof. Pat Bailey’s group working on the total synthesis of indole alkaloid natural products. After moving with Pat to Keele I was appointed to Research Fellow in 2011 and Lecturer in 2013.
My research interests are synthetic organic chemistry, medicinal and natural product chemistry and drug discovery.
Selected Publications
- 2013.
- 2012.
-
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, {5956-5969}. doi>2010.
- 2009.
-
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, {4986-4999}. doi>2008.
Full Publications List show
Journal Articles
-
Active Learning Techniques to Build Problem Solving Skills in Chemistry Students. Journal of Academic Development and Education. full text>2018.
- 2013.
- 2012.
-
Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, {5942-5955}. doi>2010.
-
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, {5956-5969}. doi>2010.
- 2009.
-
Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, {379-388}. doi>2009.
-
Debenzylation using catalytic hydrogenolysis in trifluoroethanol, and the total synthesis of (-)-raumacline. Tetrahedron letters, vol. 49, 2150-2153. doi>2008.
-
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, {4986-4999}. doi>2008.
-
From fragment to lead: High throughput crystallography and rational design to identify CDKs inhibitors as anticancer drugs. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, Sept. 10-14, 2006, COMP-405.2006.
-
Palladium catalysed cross-coupling reactions of silylamines. CHEMICAL COMMUNICATIONS, 1976-1977. doi>2004.
-
Homogeneous catalysis in supercritical carbon dioxide. Carbon Dioxide Recovery and Utilization, 149-168.2003.
-
Carbon dioxide as a solvent for polymerization and cross coupling reactions. Preprints of Symposia - American Chemical Society, Division of Fuel Chemistry, vol. 47, 282-283.2002.
-
Palladium-catalyzed cross-coupling reactions in supercritical carbon dioxide. Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002, ORGN-464.2002.
-
Palladium-catalysed cross-coupling reactions in supercritical carbon dioxide. CHEMICAL COMMUNICATIONS, 1966-1967. doi>2001.
Other
-
Amination of aromatic compounds using transition metal catalysts.2005.
-
Chemical reactions in compressed carbon dioxide using palladium catalysts.2003.
-
Microencapsulated transition metal reagents for reactions in supercritical fluids.2003.
-
Pharmaceutical compounds such as substituted thiazole and isothiazole derivatives and their preparation, pharmaceutical compositions, formulations, and use in prophylaxis or treatment of disease states or conditions mediated by cyclin dependent kinase such as cancers, fungal infections or agricultural use.2006.
-
Preparation of 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators.2005.
-
Preparation of 4-amino-3-pyrazolecarboxamides as CDK2 kinase inhibitors.2006.
-
Preparation of hydroxybenzamides as Hsp90 inhibitors.2006.
-
Preparation of pyrazole derivatives for use in pharmaceutical compositions for the inhibition of cyclin dependent kinases and glycogen synthase kinases.2006.
-
Preparation of pyrazoles as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinase.2005.
-
Preparation of thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases.2006.
CHE-00027: General and Organic Chemistry
CHE-00029: General and Organic Chemistry for Health
CHE-20001: Organic Synthesis and Chirality (tutorials)
CHE-20027: Medicinal and Biological Chemistry 1 (Module Leader)
CHE-30047: Medicinal and Biological Chemistry 2 (Module Leader)
CHE-30044: Topics in Medicinal Chemistry
CHE-40023: Applied Chemistry Topics (Module Leader)
CHE-30002: Dual Honours Research Project
CHE-30040: Chemistry Research Project
CHE-30041: Medicinal Chemistry Research Project
CHE-40021: MChem Research Project
I enjoy promoting the understanding of what molecules are through hands-on outreach activities. I created the Molecules Network - a group of schools committed to molecules based science outreach in their communities.
See the Make-it-Molecular website for more information.